[ad_1]
HONG KONG (Reuters) – China’s Fosun Pharmaceutical Group (600196.SS) said users of its mobile health app in China were using BioNTech’s (22UAy.DE) vaccine to boost COVID-19 in Hong Kong. Announced that you can now register to be inoculated with shots.
According to the Shanghai-listed company, the booster shots offered are recommended for people over the age of 18, and for those who have completed their first vaccination course.
The announcement comes as mainland China takes a major step toward easing COVID-19 border controls, and Chinese policymakers see the Omicron variant of the novel coronavirus as less virulent.
China has so far insisted on using only Chinese-made vaccines. This is an inactivated virus type and not based on Western mRNA technology – use it on your own population.
BioNTech and its Chinese partner Fosun have obtained approval for a COVID-19 vaccine adapted to Omicron’s BA.4 and BA.5 variants for people over the age of 12 in Hong Kong, the German company said. said Dec. 23.
The vaccine is the first and currently the only variant-adapted vaccine available as a booster dose for individuals over the age of 12 licensed in Hong Kong, BioNTech said at the time.
Fosun did not immediately respond to a request for comment.
A shipment of the BioNTech COVID-19 vaccine intended for German nationals in China arrived at the German embassy in Beijing last week as cases surged in China after policymakers withdrew nearly all previous epidemic control protocols. Did.
Reporting by Meg Shen and Ryan Wu. Edited by Andrew Heavens and Muralikumar Anantharaman
Our Standards: Thomson Reuters Trust Principles.
[ad_2]
Source link
